Cefradex — Competitive Intelligence Brief

Cefradex (cefradine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cefradine. Area: Immunology.

marketed cefradine Matrix metalloproteinase-9 Immunology

Target snapshot

Cefradex (cefradine) — Bristol-Myers Squibb.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cefradex TARGET	cefradine	Bristol-Myers Squibb	marketed	cefradine	Matrix metalloproteinase-9	1974-01-01
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
Monocid	CEFONICID		marketed	cefonicid	Matrix metalloproteinase-9	1984-01-01
Dtic-Dome	dacarbazine	Bayer	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1975-01-01
Busulfex	busulfan	Waylis	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1954-01-01
Rhinocort	Rhinocort	Marinomed Biotech AG	marketed		Matrix metalloproteinase-9, Probable G-protein coupled receptor 97, Glucocorticoid receptor
Chlorhexidin	Chlorhexidin	Krishnadevaraya College of Dental Sciences & Hospital	marketed		Synaptojanin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cefradine class)

1. Bristol-Myers Squibb · 1 drug in this class